Zejula is a groundbreaking medicine that has revolutionized the treatment of ovarian cancer. It is the first and only once-daily oral medicine of its kind. But who makes Zejula? This article will explore the company behind this revolutionary medicine and how it got its start. Through understanding the history of Zejula’s manufacturer, we can gain insight into how they continue to shape the treatment of ovarian cancer today.
Zejula (niraparib) is a prescription medication used to treat advanced ovarian cancer in adults. It is manufactured by Tesaro, a biopharmaceutical company based in Waltham, Massachusetts.
Who Makes Zejula?
Zejula (niraparib) is a prescription medication used to treat metastatic breast cancer and certain types of ovarian cancer. It is a poly ADP-ribose polymerase (PARP) inhibitor, meaning it works by blocking an enzyme that helps cancer cells repair themselves. Zejula is made by Tesaro, a biopharmaceutical company based in Waltham, Massachusetts.
History of Tesaro
Tesaro was founded in 2010 by Lonnie Moulder, a former executive at Genentech, and Mary Lynne Hedley, a former executive at ImClone Systems. The company was initially focused on developing and commercializing treatments for cancer and other serious diseases. In 2013, Tesaro acquired rights to Zejula from Merck, and the drug was approved by the US Food and Drug Administration (FDA) in 2017.
Products Offered
In addition to Zejula, Tesaro offers several other products and services, including:
- Varubi (rolapitant): an anti-emetic used to prevent nausea and vomiting caused by chemotherapy
- VARUBI IV: an intravenous version of Varubi
- Zepzelca (lurbinectedin): an investigational treatment for certain types of metastatic non-small cell lung cancer
- Immuno-oncology services: Tesaro provides clinical trial and consulting services to help pharmaceutical companies develop treatments for cancer.
Future Plans
Tesaro is currently working on developing treatments for a variety of cancers, including prostate, stomach, and bladder. The company is also researching potential treatments for rare diseases, such as Angelman syndrome and Prader-Willi syndrome.
Related FAQ
Who Makes Zejula?
Answer: Zejula is a prescription medicine used to treat certain types of ovarian, fallopian tube, and primary peritoneal cancer in women who have already been treated with chemotherapy. The medication is manufactured by the pharmaceutical company, Tesaro, Inc.
What is the Active Ingredient in Zejula?
Answer: The active ingredient in Zejula is niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. It works by blocking an enzyme called PARP, which helps cancer cells repair themselves. This stops the cancer cells from growing and dividing, leading to cell death.
How is Zejula Administered?
Answer: Zejula is administered as a capsule and is taken by mouth once a day. It is important to take the medicine at the same time each day, either with or without food. It is important to take the medicine exactly as prescribed by your doctor.
What are the Side Effects of Zejula?
Answer: Common side effects of Zejula include nausea, vomiting, constipation, fatigue, headache, and decreased appetite. Less common side effects include low white blood cell count, anemia, hair loss, rash, and fever. It is important to contact your doctor if you experience any of these side effects.
What is the Cost of Zejula?
Answer: The cost of Zejula varies depending on insurance coverage and other factors. According to GoodRX, the cash price for 30 capsules of Zejula 200mg is approximately $5,400. It is important to speak to your doctor or pharmacist about the cost of Zejula and any potential savings programs that may be available.
What is the Mechanism of Action of Zejula?
Answer: The mechanism of action of Zejula is to block an enzyme called PARP (poly ADP-ribose polymerase). PARP helps cancer cells repair themselves and by blocking this enzyme, Zejula stops the cancer cells from growing and dividing, leading to cell death.
In conclusion, Zejula is a revolutionary drug developed by Tesaro, Inc., a US-based pharmaceutical company. It has been approved by the US Food and Drug Administration for the treatment of relapsed ovarian cancer and is now available in the United States. Zejula is a breakthrough in cancer treatment and offers hope to those suffering from this aggressive form of cancer. With its powerful combination of safety and efficacy, Zejula is a game-changer in the fight against ovarian cancer.